CTRI/2024/07/071353尚未招募4 期
A Multi-Centric, Active Post Marketing Surveillance Study to Assess the Safety and Efficacy of Tofacitinib Extended Release Tablets 11 mg for the Treatment of Adult Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis - NI
Sun Pharmaceutical Industries Limited (SPIL)0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Patients of either gender, aged between greater than or equal to 18 years to lesser than or equal to 65 years
- •2.Patient with moderately to severely active Rheumatoid Arthritis, OR active Psoriatic Arthritis, OR moderately to severely Ulcerative Colitis, as per the treating physician’s clinical judgment (Physician Global Assessment)
- •3.Patients who are willing to provide informed consent to collect the surveillance data
排除标准
- •1.Patients with history of intolerance or hypersensitivity to any of the Tofacitinib including its components
- •2.Patient with any clinically significant disorder that, in the opinion of the treating physician would result in jeopardizing patient safety and his/ her inability to understand and comply with the requirements of the surveillance
- •3.Pregnant women and nursing mothers
研究者
相似试验
招募中
4 期
Post Marketing Observational Study to Assess Safety and suitability of Vildagliptin 100mg SR formulation in Type 2 Diabetes Mellitus (T2DM) patientsCTRI/2022/10/046453Abbott Healthcare Pvt Ltd
尚未招募
4 期
Enzobiotics Post Marketing surveillance studyCTRI/2024/07/071372Mylin Biotech India Private Limited
进行中（未招募）
不适用
Study to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals’ rotavirus vaccine, when administered in Filipino subjects aged at least 6 weeks at the time of first vaccination.EUCTR2012-004039-21-Outside-EU/EEAGlaxoSmithKline1,439
进行中（未招募）
不适用
An open, multicentric, post-marketing surveillance (PMS) study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib vaccine administered at 3, 4, 5 and 18 months of age, in healthy infantsHealthy volunteers (Primary immunization of healthy infants at 3, 4 and 5 months of age with a booster dose at 18 months of age, against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b diseases).EUCTR2015-001512-35-Outside-EU/EEAGlaxoSmithKline Biologicals4,500
进行中（未招募）
不适用
A PMS study to assess the safety and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib and INFANRIX HEXA™ vaccines when administered as a primary vaccination course, followed by admini-stration of GSK Biologicals’ DTPa-IPV/Hib vaccine as a booster dose in toddlers.EUCTR2012-002439-26-Outside-EU/EEAGlaxoSmithKline Biologicals702